CA Patent

CA3148115A1 — Method of treating cancer

Assigned to Laekna Ltd · Expires 2021-02-11 · 5y expired

What this patent protects

The present application provides a method of treating castrate resistant prostate cancer in a patient, comprising administering to the patient a combination of afuresertib and CFG920, wherein the castrate resistant prostate cancer is also resistant to one or more standard of care…

USPTO Abstract

The present application provides a method of treating castrate resistant prostate cancer in a patient, comprising administering to the patient a combination of afuresertib and CFG920, wherein the castrate resistant prostate cancer is also resistant to one or more standard of care treatments.

Drugs covered by this patent

Patent Metadata

Patent number
CA3148115A1
Jurisdiction
CA
Classification
—
Expires
2021-02-11
Drug substance claim
No
Drug product claim
No
Assignee
Laekna Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.